Plain-English translation of NCT06675357 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new imaging approach called FAPI PET/MRI that may help doctors better identify and monitor prostate cancer. The study focuses on how a special tracer called FAPI binds to certain cells in cancer tissue, which could make it easier to spot cancer that has spread. Researchers hope this imaging method will improve how doctors diagnose and track prostate cancer over time.
Current imaging methods for advanced prostate cancer have limitations, and doctors need better tools to detect where cancer has spread in the body. This medication may offer a new way to identify cancer cells more accurately, helping doctors make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would visit the research center twice for PET/MRI imaging scans, with each visit lasting up to 2.5 hours. During these visits, you'll receive an injection of a special tracer (the medication being tested) and then undergo the combined PET/MRI scan, which takes pictures to help doctors see if cancer has spread. The scans are non-invasive and painless, similar to other imaging tests you may have already had for your cancer care.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Wisconsin, Madison
Enrollment target
~30 participants
Started
February 2026
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Radiology Studies
University of Wisconsin, Madison
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.